Glimepiride orally disintegrating tablets

This product is a third-generation sulfonylurea long-acting antidiabetic drug. Its mechanism of action is to bind to the sulfonylurea receptor (protein with a relative molecular mass of 6.5×104) on the surface of pancreatic β-cells. This receptor is coupled to the ATP-sensitive K (KATP) channel, which promotes the closure of the KATP channel, causes the depolarization of the cell membrane, opens the voltage-dependent calcium channel, and promotes the release of insulin by the influx of Ga2, and inhibits the synthesis of liver glucose. Recent studies have shown that different sulfonylurea drugs have different affinities with KATP. The order is: Glyburide = Glimepiride Tolbutamide Chlorpropamide. In addition, Glimepiride can also increase the uptake of cardiac glucose through non-insulin-dependent pathways, which may be due to the increased expression of two proteins of glucose transporter factors 1 and 4. Since the effect of Glimepiride on cardiovascular KATP channels is weaker than that of Gliboride, Gliclazide and Glipizide, there are few adverse cardiovascular reactions.

The main ingredient of this product is glimepiride.

This product is an orally disintegrating tablet.

Patients with type 2 diabetes who have not been able to control their blood sugar with diet and exercise alone.

This product is an orally disintegrating tablet. When used, the tablet can be quickly disintegrated by placing it in the mouth. No or only a small amount of water is needed, and there is no need to chew. After disintegration, it enters the digestive tract through swallowing to take effect. Once a day.

Observations of 4,200 patients showed that the product was well tolerated. The incidence of hypoglycemia was 0.9% to 1.7%, and other possible adverse reactions included dizziness (1.7%), weakness (1.6%), headache (1.5%), and nausea (1.1%). Rare adverse reactions such as vomiting, abdominal pain, diarrhea, and skin allergies occurred at a rate of 1%.

Not yet clear.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Use with caution. Precautions for the elderly: Follow doctor's advice.

.When this product is taken with other drugs with high protein binding rates, the AUC and Cmax of this product are reduced by 34% and 4% respectively due to competitive binding with serum proteins, but the concentrations of glucose and C-peptide in plasma are not changed. Propranolol can significantly increase the Cmax, AUC and T1/2 of this product by 23%, 22% and 15% respectively, and reduce CL/F by 18%. When taken with ACE inhibitors, the hypoglycemic effect of this product may be enhanced. 2. When used in combination with one of the following drugs that have enhanced hypoglycemic effects, hypoglycemia may occur, such as: insulin, other hypoglycemic drugs, ACE inhibitors, allopurinol, anabolic steroids and male sex hormones, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, pheniramine,

Seal and store in a dry place.

2mg

24 months

Wuhan Weiao Pharmacauti Cal Co., Ltd.

• Founded in:

  1996-10-30

• Address:

  Wuhan University Science and Technology Park, Jiangxia Avenue, East Lake New Technology Development Zone, Wuhan

• Tax NO.:

  91420100616432784K

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view